Privia Health Group, Inc. (NASDAQ:PRVA) Shares Purchased by US Bancorp DE

US Bancorp DE lifted its holdings in Privia Health Group, Inc. (NASDAQ:PRVA) by 6.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,058 shares of the company’s stock after purchasing an additional 1,134 shares during the quarter. US Bancorp DE’s holdings in Privia Health Group were worth $353,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PRVA. Riverbridge Partners LLC boosted its position in shares of Privia Health Group by 19.7% in the 4th quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company’s stock worth $113,868,000 after purchasing an additional 958,418 shares in the last quarter. Eventide Asset Management LLC boosted its position in shares of Privia Health Group by 979.2% in the 3rd quarter. Eventide Asset Management LLC now owns 822,438 shares of the company’s stock worth $14,977,000 after purchasing an additional 746,231 shares in the last quarter. Icon Wealth Advisors LLC boosted its position in shares of Privia Health Group by 1,910.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 300,889 shares of the company’s stock worth $5,479,000 after purchasing an additional 285,920 shares in the last quarter. FMR LLC boosted its position in shares of Privia Health Group by 1.5% in the 3rd quarter. FMR LLC now owns 18,169,043 shares of the company’s stock worth $330,858,000 after purchasing an additional 271,645 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Privia Health Group by 240.3% in the 3rd quarter. Barclays PLC now owns 224,018 shares of the company’s stock worth $4,079,000 after purchasing an additional 158,188 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. JMP Securities set a $29.00 price objective on Privia Health Group in a research report on Friday, February 28th. Piper Sandler lifted their price target on Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and set a $26.00 price target on shares of Privia Health Group in a research report on Thursday, January 2nd. Needham & Company LLC lifted their price target on Privia Health Group from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group lifted their price target on Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Privia Health Group currently has a consensus rating of “Buy” and a consensus price target of $26.67.

Privia Health Group Stock Performance

NASDAQ PRVA opened at $23.38 on Friday. The stock has a 50-day simple moving average of $23.29 and a two-hundred day simple moving average of $20.89. The firm has a market capitalization of $2.82 billion, a P/E ratio of 233.82, a PEG ratio of 3.47 and a beta of 0.85. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $26.04.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.